Literature DB >> 12713872

Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells.

Takashi Maeda1, Paul Sepe, Stephanie Lahousse, Seishu Tamaki, Munetomo Enjoji, Jack R Wands, Suzanne M de la Monte.   

Abstract

BACKGROUND: Aspartyl (asparaginyl) beta-hydroxylase (AAH) is an alpha-ketoglutarate-dependent dioxygenase that hydroxylates aspartate and asparagine residues in EGF-like domains of proteins. The consensus sequence for AAH beta-hydroxylation occurs in signaling molecules such as Notch and Notch homologs, which have roles in cell migration. AIM: This study evaluated the potential role of AAH in cell migration using cholangiocarcinoma cell lines as models due to their tendency to widely infiltrate the liver.
METHODS: Five human cholangiocarcinoma cell lines established from human tumors were examined for AAH expression and motility. The effect of antisense oligodeoxynucleotide inhibition of AAH on cholangiocarcinoma cell migration was investigated.
RESULTS: Western blot analysis detected the approximately 86 kDa AAH protein in all five cholangiocarcinoma cell lines, and higher levels of AAH in cell lines derived from moderately or poorly differentiated compared with well-differentiated tumors. Immunocytochemical staining and fluorescence activated cell sorting analysis revealed both surface and intracellular AAH immunoreactivity. Using the phagokinetic non-directional migration assay and a novel ATPLite luminescence-based directional migration assay, we correlated AAH expression with motility. Correspondingly, antisense and not sense or mutated antisense AAH oligodeoxynucleotides significantly inhibited AAH expression and motility in cholangiocarcinoma cells.
CONCLUSIONS: AAH over-expression may contribute to the infiltrative growth pattern of cholangiocarcinoma cells by promoting motility.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12713872     DOI: 10.1016/s0168-8278(03)00052-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  38 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

2.  A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma.

Authors:  Arihiro Aihara; Chiung-Kuei Huang; Mark J Olsen; Qiushi Lin; Waihong Chung; Qi Tang; Xiaoqun Dong; Jack R Wands
Journal:  Hepatology       Date:  2014-08-25       Impact factor: 17.425

3.  Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma.

Authors:  Katsuya Nagaoka; Xuewei Bai; Kosuke Ogawa; Xiaoqun Dong; Songhua Zhang; Yanmei Zhou; Rolf I Carlson; Zhi-Gang Jiang; Steve Fuller; Michael S Lebowitz; Hossein Ghanbari; Jack R Wands
Journal:  Cancer Lett       Date:  2019-02-12       Impact factor: 8.679

4.  Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma.

Authors:  Masafumi Shimoda; Yoshito Tomimaru; Kevin P Charpentier; Howard Safran; Rolf I Carlson; Jack Wands
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

5.  Targeting Aspartate Beta-Hydroxylase with the Small Molecule Inhibitor MO-I-1182 Suppresses Cholangiocarcinoma Metastasis.

Authors:  Katsuya Nagaoka; Kousuke Ogawa; Chengcheng Ji; Kevin Y Cao; Xuewei Bai; Joud Mulla; Zhixiang Cheng; Jack R Wands; Chiung-Kuei Huang
Journal:  Dig Dis Sci       Date:  2020-05-22       Impact factor: 3.199

6.  siRNA inhibition of aspartyl-asparaginyl β-hydroxylase expression impairs cell motility, Notch signaling, and fetal growth.

Authors:  Fusun Gundogan; Armando Bedoya; Jeffrey Gilligan; Emily Lau; Princess Mark; Monique E De Paepe; Suzanne M de la Monte
Journal:  Pathol Res Pract       Date:  2011-09-08       Impact factor: 3.250

7.  Role of aspartyl-(asparaginyl)-β-hydroxylase mediated notch signaling in cerebellar development and function.

Authors:  Elizabeth Silbermann; Peter Moskal; Nathaniel Bowling; Ming Tong; Suzanne M de la Monte
Journal:  Behav Brain Funct       Date:  2010-11-04       Impact factor: 3.759

8.  Ethanol inhibition of aspartyl-asparaginyl-beta-hydroxylase in fetal alcohol spectrum disorder: potential link to the impairments in central nervous system neuronal migration.

Authors:  Suzanne M de la Monte; Ming Tong; Rolf I Carlson; Jade J Carter; Lisa Longato; Elizabeth Silbermann; Jack R Wands
Journal:  Alcohol       Date:  2009-05       Impact factor: 2.405

9.  PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair.

Authors:  Maoyin Pang; Suzanne M de la Monte; Lisa Longato; Ming Tong; Jiman He; Rajeeve Chaudhry; Kevin Duan; Jiyun Ouh; Jack R Wands
Journal:  J Hepatol       Date:  2009-03-20       Impact factor: 25.083

10.  Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.

Authors:  C A Barton; B S Gloss; W Qu; A L Statham; N F Hacker; R L Sutherland; S J Clark; P M O'Brien
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.